Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > BUSINESS
BUSINESS
- Shionogi Scores Record Operating Profit as Royalties Spike
May 12, 2016
- Mitsubishi Tanabe’s Sales Rise on Royalty, Upfront Revenues
May 12, 2016
- Baxalta Sues Chugai over Hemophilia A Drug Patent
May 12, 2016
- Ono Delivers Record Sales on Buoyant Opdivo, FY2016 Outlook Tops 250 Billion Yen
May 12, 2016
- Astellas Logs Record Earnings on Bullish Xtandi in FY2015
May 12, 2016
- Entyvio on Track to Rake in US$2 Billion in FY2018, Ninlaro Eyed as Next Big Seller
May 11, 2016
- Takeda Drops Diabetic Nephropathy Drug amid Change in R&D Strategy
May 11, 2016
- Takeda Enjoys Higher Revenues and Profits as Entyvio Sales Triple
May 11, 2016
- Meiji Seika Pharma Jettisons BPH Treatment
May 11, 2016
- AZ Set to Double Japan Sales by 2020 on Cancer Meds, No Patent Cliff in Sight: Local Pres. Baertschi
May 11, 2016
- Taiho Establishes Venture Capital Unit in US to Invest in Field of Oncology
May 11, 2016
- Daiichi Sankyo Enters License Agreement with UK Company for Cell Therapy
May 11, 2016
- Aspen Japan Files Requests for Reimbursement Listing of Paxil, Valtrex AGs
May 10, 2016
- Takeda Gets US$38 Million Grant from Gates Foundation for Polio Vaccine Development
May 10, 2016
- Thorsten Poehl Takes Helm of Boehringer Japan
May 10, 2016
- D. Western Therapeutics Acquires Exclusive License to Corneal Endothelial Therapeutics from Doshisha Univ.
May 10, 2016
- Transfer of Vaccine, Blood Biz under Negotiation, All Directors to Exit in June: Kaketsuken
May 9, 2016
- Ex-Ranbaxy Shareholders Ordered to Pay 56 Billion Yen to Daiichi Sankyo
May 9, 2016
- Shingo Iwamoto to Lead Aspen Japan
May 9, 2016
- Halaven Approved for Advanced Liposarcoma in Europe: Eisai
May 9, 2016
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…